Evogene Reports Stronger-Than-Expected Earnings but Revenue Misses Estimates
Evogene (NASDAQ:EVGN) reported a narrower-than-expected loss for Q1, with an adjusted EPS of -$0.06 versus estimates of -$0.32. However, revenue came in at $334 thousand against expectations of $3 million and fell sharply from the prior year's $2.3 million. Shares dropped 5.11% pre-market due to concerns over declining sales.
Tickers: $EVGN
Topics: AI drug discovery biotechnology computational chemistry pharmaceuticals